Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Concurrent Chemoradiation Therapy And Consolidation Immunotherapy

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Active Not Recruiting1
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05888402Phase 2Active Not RecruitingPrimary

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

NCT03673657Phase 2CompletedPrimary

Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer

NCT00846443Phase 1UnknownPrimary

Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer

Showing all 3 trials

Research Network

Common Treatments

  • Concurrent Chemoradiation Therapy And Consolidation Immunotherapy1
  • Toripalimab1
  • Concurrent Pemetrexed Cisplatin And Radiotherapy1
  • Early Nutrition Intervention From The Start Of Ccrt1
  • Thoracic Radiotherapy1

Active Sponsors

  • Sun Yat-sen University1
  • Shanghai Junshi Bioscience Co., Ltd.1
  • Fudan University1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Top Investigators

Activity Timeline